News

Dalvance is the first and only IV antibiotic approved to treat ABSSSI with a two-dose regimen of 1000mg followed one week later by 500mg, each administered over 30

The license includes programs targeting type 2 diabetes (Phase 2b) and cancer cachexia (Phase 2) that Viking is currently preparing to advance into mid-to-late stage clinical trials. Viking

The company is mainly focused on the development and acquisition of late clinical-stage proprietary drugs for the treatment of inflammatory and gastrointestinal diseases and related conditions. Patient enrolment

As part of the deal, both the firms will jointly carry out a study titled ‘Development and Validation of a Human Brown Adipose Cell Model’, which will seek

Emerson Ecologics has obtained licenses to distribute prescription and injectable therapy products in 42 states. Emerson also confirmed that they will be submitting applications in the remaining states,

The approval of the drug is for patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following – splenomegaly, hepatomegaly,

The investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without RBV (weight-based),

The company intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy (DMD). The transaction, which includes about $25m in acquisition costs and

The positive opinion of the CHMP is for both kidney and liver transplant recipients and includes both the de novo transplant and switch settings, as well as for